BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX)

CUSIP: 114082100

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Equity / COM
Total 13F shares
102,346
Share change
+102,346
Total reported value
$380,000
Price per share
$3.71
Number of holders
9
Value change
+$380,000
Number of buys
9

Quarterly Holders Quick Answers

What is CUSIP 114082100?
CUSIP 114082100 identifies BTX - BROOKLYN IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) as of Q1 2021

As of 31 Mar 2021, BROOKLYN IMMUNOTHERAPEUTICS - COM (BTX) was held by 9 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 102,346 shares. The largest 9 holders included CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Virtu Financial LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, North Star Investment Management Corp., Tower Research Capital LLC (TRC), BlackRock Inc., and UBS Group AG. This page lists 9 institutional shareholders reporting positions in this security for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.